IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 4, 1997, Pages 265-272

  Berghella, Anna Maria ^a   Pellegrini, Patrizia ^a   Del Beato, Tiziana ^a   Adorno, Domenico ^a   Casciani, Carlo Umberto ^a  

^a Istituto Tipizzazione Tissutale L'Aquila   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6;

ADENOMA; ADULT; AGED; ARTICLE; CANCER INVASION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

EID: 0031459225     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.265     Document Type: Article

References (43)

1. Bishop DT, Albright LC, McLellan T, Gardner EJ, Skolnick MH Segregation and linkage analysis of nine Utah breast cancer pedigreees. Genetic Epidem 1988; 5-151.
2. Lightdale C, Lipkin M, Descner E. In vivo measurement in familial polyposis: kinetics and location of proliferating cells in colonic adenomas Cancer Res 1982;42:4280.
3. Burt RW, Skolnick MH. Hereditary factors in the pathogenesis of colorectal cancer. In:Cell and molecular biology of colon cancer Augenlicht HL (ed) CRC press, Florida, 1989; 87-96.
4. Cannon-Albright LA, Skolnick MH, Bishop T.D., Lee RG, Burt RW. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal Cancer. N Engl J Med 1988a;319:533.
5. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138.
6. Tempero M, Anderson J. Progress in colon cancer - Do molecular markers matter? N Engl J Med 1994;331:267.
7. Friedman E Difefrential response of premalignant epithelial cell classes to phorbol ester tumor promoters and to deoxycholic acid Cancer Res 1981;4:4588.
8. Wolman SR. Genetic markers of colonic neoplasia. Sem Surg Oncol 1987;3:120.
9. Wolman SR, Mastromarino AJ. Markers of colonic cell differentiation: a summary, in Markers of cell differentiation, Mastromarino AJ, Brattain MG Eds., Raven Press. New Yoek, 1984.
10. Coffey RJ, Shipley GD, Moses HL. Production of transforming growth factors by human colon cancer lines Cancer Res 1986;46:1164.
11. Berghella AM, Pellegrini P, Piancatelli D, Maccarone D, Del Beato T, Giubilei D, Pomidori A, Adorno D, Casciani CU. Progression mechanisms in colon cancer: sIL-2R, IL-2+anti-CD3 proliferative response and tumour stage correlations Cancer Immunol Immunother 1994;38:160
12. Bowker DW, Bridge PD, Dunstan FDJ, Fry JC, Iles TC, Randerson PF, Wiegert RG (1993) Biological data analysis. In: A pratical approach, Fry JC (ed) Oxford University Press, New York.
13. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996, 42-1.
14. Pellegrini P, Berghella AM, Del Beato T, Maccarone D, Adorno D, Casciam CU. Immunological directives for biotherapy improvement in the treatment of colorectal cancer. Cancer Biother & Radiopharm 1996; 11:113.
15. Contasta I, Pellegrini P, Berghella AM, Del Beato T, Canossi A, Di Rocco M, Adorno D, Casciani CU. Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer. Cancer Biother & Radiopharm 1996;11:373.
16. Berghella AM, Pellegrini P, Del Beato T, Maccarone D, Adorno D, Casciani CU Prognostic significance of immunological evaluation in colorectal cancer. Cancer Biother & Radiopharm 1996;11:355.
17. Jenkins MP, Alvaranga JC, Thomas MJ The management of retroperitonal soft tissue sarcomas. Eur J Cancer 1996;(32A)4:622.
18. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY. Multiple infusion of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomas. Eur J Cancer 1996;(32A)4:636.
19. Zier KS, Gansbacher B. Tumor cell vaccines that secrete interleukin-2 (IL-2) and interferonγ (IFNγ) are recognised by T cells while resisting destruction by natural killer (NK) cells. Eur J Cancer 1996; (32A)8:1408.
20. Bodey B, Psenko V, Lipsey AL, Kaiser HE. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms Anticancer Res 1996;16(1):219.
21. Bloom BR, Salgame P, Diamond B. Revisiting and revising suppressor T cells. Immunol Today 1992; 13:131.
22. Cher DJ, Mosmann TR. Two types of murine helper T cell clones. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987;138:3688.
23. Stevens TL, Bossie A, Sanders WM, Fernandez-Botram R, Coffman LR, Mosmann RT, Vitetta ES. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334:255.
24. + T cells. Immunol Rev 1991; 123:209.
25. + T-cell subsets in vivo. Immunol Rev 1991;123:189.
26. + T cell subsets producing a selective pattern of lymphokines in the pathogenesis of human chronic inflammatory and allergic diseases. Immunol Rev 1991;123:23.
27. Murray JS, Madri J, Pasqualini T, and Bottomly K. Functional CD4 T cell subset interplay in an intact immune system. J Immunol 1993;150:4270.
28. Thomson AW, Dinarello CA, Goldsmith MA, Greene WC, Bancherau J, Rybak ME, Hirano T, Mosman TR, De Maeyer E, De Maeyer-Guignard J, Tracey KS, Pugh-Humphreys RGP (1994) In: The cytokine handbook - Thomson A. (ed.) Academic press inc. San Diego, CA.
29. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, and Köhler G. Disruption of the murine IL-4 gene blocks TH2 cytokine responses. Nature 1993; 362:245.
30. Tanaka T, Hu-Li J, Seder RA, Fazekas de St.Groth B, and Paul WE. Interleukin 4 suppresses interleukin 2 and interferon production by naive T cells stimulated by accessory cell-dependent receptor engagement Proc Natl Acad Sci USA 1993; 90:5914.
31. Chen L, Tourvielle B, Burns GF, Bach FH, Mathieu-Mahul D, Sasportes M, and Bensussan A. Interferon: a cytotoxic T lymphocyte differentiation signal Eur J Immunol 1986;16:767.
32. Gillis S, Gillis AE, and Henney CS. Monoclonal antibody directed against IL-2: inhibition of T lymphocyte mitogenesis and in vitro differentiation of alloreactive cytotoxic T cells. J Exp Med 1981;154:983.
33. Maraskovsky E, Chen WF, Shortman K. EL-2 and IFN-are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989;143:1210
34. Wagner H, Hardt C, Rouse BT, Roellinghoff M, Scheurich P, Pfizenmaier K. Dissecrion of the proliferative and differentiation signals controlling murine cytotoxic T lymphocyte responses. J Exp Med 1982;155:1876.
35. + cytotoxic T lymphocytes. J Immunol 1989;143:1518.
36. + precursor subpopulations J Immunol 1992;149:2489.
37. Mulé JJ, Custer MC, Travis WD, and Rosenberg SA. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 1992;148:2622.
38. Bradley LM, Yoshimoto K, Swain SL The cytokines IL-4, IFN-gamma, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro. J Immunol 1995; 155:1713.
39. Banchereau J. Converging and diverging properties of human interleukin-4 and interleukin-10. Behring Institute Mitteilungen 1995; 96:58.
40. Fossa SD, Aamdal S, Naume B, Gallati H. Serum levels of cytokines and soluble cytokines receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2 interferon-alpha combination therapy. Acta Oncol 1995;34:599.
41. Lopez M, Dilauro L, Paoletti G, Santini S, Grandolfo GM, Vitelli G, Sfrasca AM, Ameglio F, Rasi G, Garaci E. Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2-clinical and immunological effects. Annals Oncol 1995;6:1011.
42. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, Kadin ME. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma-clinical and prognostic implications. Arch Dermatol 1996;132:42.
43. Rothlein R, Mainolfi EA, Czjkowski M, Marlin S. A form of circulating ICAM-1 in human serum J Immunol 1991;147:3788.